NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
A dominant frontoparietal beta oscillatory brain state in the days after psilocybin and 5-MeO-DMT
This observational EEG study (n=42) found that people who had used psilocybin/LSD or 5-MeO-DMT within the previous three weeks showed a dominant right frontoparietal beta-wave brain state, linked to the time since use...
Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session
This double-blind, placebo-controlled crossover pilot study (n=4) compared oral Δ9-THC (25 or 50 mg) with psilocybin (25 mg) and placebo in healthy adults during a psychedelic therapy-style session. A 25 mg dose of Δ9...
Non-Ordinary States of Consciousness and Psychedelic Integration with Psychologist Nigel Denning
Nigel Denning explores how non-ordinary states of consciousness can quiet the brain’s default patterns, allowing us to access deep psychological symbolism for personal transformation. Therapeutic facilitation requires...
A Closer Look at Definium’s Phase 3 LSD for GAD Readout
Earlier this month, we covered Definium Therapeutics’ second Phase 3 readout, this time pertaining to its first LSD (DT120) for generalised anxiety disorder (GAD) study. (See Smooth Sailing: Definium’s LSD Voyage Hits...
Was Carlos Castaneda Among the First Psychedelic Grifters?
Author Carlos Castaneda built a fortune on a fabricated Indigenous lineage. A new biography shows how his blueprint still runs the psychedelic underground. [...] Read More... The post Was Carlos Castaneda Among the Fi...
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market TEL AVIV, Israel, Aug.…
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK, August 26, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…
Experic LLC has applied to register as an importer of basic classes of controlled substances.
Experic LLC submitted an application to be registered as an importer of basic classes of controlled substances. Further information about the drugs covered by the application is provided in the supplementary information.
Researchers found direct structural evidence that ketamine binds to and partially activates all three major human opioid receptors, alongside its established NMDA receptor action.
A team led by Tao Che at Washington University School of Medicine found that ketamine binds to and activates mu, kappa and delta opioid receptors, with stronger effects at mu and kappa. Cryo-electron microscopy showed...
Definium Therapeutics’ first Phase 3 study of LSD compound DT120 for generalised anxiety disorder met its primary and key secondary endpoints, prompting further analysis of the topline data.
The analysis examines DT120’s first Phase 3 readout for generalised anxiety disorder after the study met its primary and key secondary endpoints. Researchers highlighted 14% remission and 43% response rates after a si...
A unique psychedelic shows promise for pain and stroke
An unusual psychedelic found in Salvia divinorum shows promise for treating pain, addiction, and stroke in animal models. However, anxiety-inducing side effects and a fleeting duration mean modified versions may be ne...
University of Miami’s Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science
Washington, D.C., August 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the announcement that the University of Miami has gifted the federal government its 1994 ibogaine Invest...
Who Gets to Heal?
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether documented suffering should remain the price of admission to psychedelic care. The post Who Gets to...
Kinetochem LLC has applied to register as a bulk manufacturer of basic classes of controlled substances.
The Drug Enforcement Administration published Kinetochem LLC’s application on 25 August 2026. Public comments are open until 26 October 2026, but the available information does not specify the controlled substances in...
Scottsdale Research Institute SRI Montana Satellite Laboratory has applied to register as a bulk manufacturer of basic classes of controlled substances.
The Drug Enforcement Administration published the application on 25 August 2026. Public comments are open until 26 October 2026, but the available information does not specify which controlled substances are covered.